Changing Proportions of HIV-1 Subtypes and Transmitted Drug Resistance Among Newly Diagnosed HIV/AIDS Individuals - China, 2015 and 2018.

Authors:

Jingjing Hao Shan Zheng Mengze Gan Aobo Dong Ruihua Kang Miaomiao Li Shuai Zhao Jing Hu Chang Song Lingjie Liao Yi Feng Yiming Shao Yuhua Ruan Hui Xing

China CDC Wkly 2021 Dec;3(53):1133-1138

State Key Laboratory of Infectious Disease Prevention and Control (SKLID), National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China.

Introduction: With the expansion of human immunodeficiency virus (HIV) antiretroviral therapy (ART), HIV drug resistance is becoming more and more serious. This study describes the changing prevalence of HIV-1 subtypes and transmitted drug resistance (TDR) among newly diagnosed individuals in China, 2015 and 2018.

Methods: A total of 8,980 individuals in 2015 and 2018 from 31 provincial-level administrative divisions (PLADs) were enrolled in this study. Viral RNAs were amplified and sequenced using an in-house polymerase chain reaction (PCR) protocol. The Stanford HIV Drug Resistance Database (HIVdb) was used to predict susceptibility to 12 antiretroviral drugs.

Results: The prevalence of TDR was not significantly increased over time. The prevalence of TDR was 3.8% and 4.4% in 2015 and 2018, respectively (=0.13). The prevalence of CRF55_01B increased from 2.3% in 2015 to 3.9% in 2018 (<0.001). The drug resistance prevalence of non-nucleoside reverse transcriptase inhibitors (NNRTI) increased from 2.4% in 2015 to 3.3% in 2018 (0.01). The prevalence of E138 (<0.001), H221 (=0.03), and V179 (<0.001) mutations increased from 0.30%, 0.09%, and 0.70% in 2015 to 1.10%, 0.30%, and 1.70% in 2018, respectively.

Conclusions: HIV drug resistance affects the effect of antiretroviral treatment, so the monitoring of HIV TDR should be strengthened to control the transmission of HIV drug resistance.

Download full-text PDF	Source
http://dx.doi.org/10.46234/ccdcw2021.251	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742141	PMC

December 2021

Publication Analysis

Top Keywords

predict susceptibility

diagnosed individuals

Keyword Occurance

Similar Publications

Phytochemical modulation of P-Glycoprotein and its gene expression in an ivermectin-resistant Haemonchus contortus isolate in vitro.

Authors:

Poliana Araújo Pacheco Helder Louvandini Rodrigo Giglioti Bruna Costa Rodrigues Wedy Jessica Carolina Ribeiro Cecilia José Verissimo Jorge Freire da Silva Ferreira Alessandro Francisco Talamini do Amarante Luciana Morita Katiki

Vet Parasitol 2022 May 18:109713. Epub 2022 May 18.

Instituto de Zootecnia (SAA-IZ), Nova Odessa, SP, Brazil. Electronic address:

Haemonchus contortus is the most important gastrointestinal nematode in small ruminant systems worldwide and has developed resistance to several drugs, including ivermectin (IVM). IVM is not only a veterinary drug but also a safe, broad-spectrum, antiparasitic drug used in humans. One of the main IVM-resistance mechanisms in H. Read More

View Article and Full-Text PDF

May 2022

Similar Publications

Comparison of endogenous development, invasion ability and apoptotic features between diclazuril resistant and sensitive strains of Eimeria tenella.

Authors:

Junjie Huang Jie Huang Hosam Mohamed Husien Weilong Peng Mingjiang Liu Ruonan Bo JinGui Li

Vet Parasitol 2022 May 14:109719. Epub 2022 May 14.

College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, PR China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, PR China. Electronic address:

Diclazuril (DIC) is widely used in the poultry industry to control coccidiosis. However, drug resistance makes it less effective, and the underlying mechanism remains unclear. One DIC-resistant E. Read More

View Article and Full-Text PDF

May 2022

Similar Publications

In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and/or amphotericin B.

Authors:

Pilar Escribano Ana Gómez Elena Reigadas Patricia Muñoz Jesús Guinea

Clin Microbiol Infect 2022 May 18. Epub 2022 May 18.

Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain. Electronic address:

Objectives: New antifungal drugs, such as olorofim, may overcome the problem of resistance in Aspergillus fumigatus. We here report the activity of olorofim against a set of A. fumigatus sensu lato recently collected in Spain. Read More

View Article and Full-Text PDF

May 2022

Similar Publications

Cabenuva: the last FDA-approved drug to treat HIV.

Authors:

Elahe Taki Faezeh Soleimani Arezoo Asadi Hossein Ghahramanpour Ali Namvar Mohsen Heidary

Expert Rev Anti Infect Ther 2022 May 20. Epub 2022 May 20.

Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Introduction: The conventional combination antiretroviral therapy (cART) besides all its benefits, exhibited poor adherence to daily pill administration, life-long treatment period and emergence of viral resistance. The development of long-acting (LA) drugs have changed the management of common medical conditions for human immunodeficiency virus (HIV). Cabenuva is the first LA antiretroviral injectable drug composed of nano-formulation of cabotegravir (CAB) and rilpivirine (RPV). Read More

View Article and Full-Text PDF

May 2022

Similar Publications

}

Search Our Scientific Publications & Authors